Document:

Exhibit 10.13

 

THIS WARRANT AND THE UNDERLYING SECURITIES
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH TRANSACTION UNDER APPLICABLE SECURITIES LAWS OR UNLESS OFFERED, SOLD, PLEDGED,
HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE
ENTITLED TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

REVELATION
BIOSCIENCES, INC.

 

COMMON STOCK WARRANT

 

January 31, 2021

 

Void After January 31, 2027

 

THIS CERTIFIES THAT, for value received
and subject to the terms and conditions set forth below, National Securities Corporation, or assigns (the “Holder”),
is entitled to subscribe for and purchase at the Exercise Price (defined below) from Revelation Biosciences, Inc., a Delaware corporation
(the “Company”), Sixty-One Thousand Six-Hundred (61,600) fully-paid and non-assessable shares of Common Stock
of the Company. This Warrant is being issued pursuant to that certain Placement Agent Agreement by and between the National Securities
Corporation and the Company, dated January 27, 2021 (the “Agreement”).

 

		1.	DEFINITIONS. As used herein, the following terms shall have the following respective meanings:

 

“Common Stock” shall
mean the Company’s Common Stock, par value $0.001 per share.

 

“Exercise Period” shall
mean the period commencing on the date of issuance and ending six years after the date of issuance, January 31, 2027, unless sooner terminated
as provided below.

 

“Exercise Price” shall
mean $7.31 per share of Common Stock.

 

“Sale of the Company”
shall mean (i) a transaction or series of related transactions with one or more non-affiliates, pursuant to which such non-affiliate(s)
acquires capital stock of the Company or the surviving entity, in either case, possessing the voting power to elect a majority of the
board of directors or a majority of the outstanding capital stock of the Company or the surviving entity (whether by merger, consolidation,
sale or transfer of the Company’s outstanding capital stock or otherwise); or (ii) the sale, lease or other disposition (including
exclusive license) of all or substantially all of the Company’s assets or any other transaction resulting in all or substantially
all of the Company’s assets being converted into securities of any other entity or cash; provided, however, that the sale by the
Company of capital stock for the purpose of financing its business shall not be deemed to be a Sale of the Company.

 

“Warrant Shares” shall
mean the shares of the Company’s Common Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms
herein, including but not limited to adjustment pursuant to Section 5 below.

 

		2.	EXERCISE OF WARRANT.

 

(a) Method of Exercise. The rights represented
by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company:

 

		i)	an executed Notice of Exercise in the form attached hereto;

 

		ii)	this Warrant; and

 

		iii)	Payment:

 

     

     

    

 

(1) Payment of the then-applicable Exercise Price
per share multiplied by the number of Warrant Shares being purchased upon exercise of the Warrant (such amount, the “Aggregate
Exercise Price”) made in the form of cash, or by certified check, bank draft or money order payable in lawful money of the
United States of America or in the form of a Cashless Exercise to the extent permitted in Section 2(a)(iii)(2) below.

 

(2) If at the time of exercise there is no effective
registration statement for the resale of the Warrant Shares, or the prospectus contained therein is not available for use, the Holder
may, in its sole discretion, exercise all or any part of the Warrant in a “cashless” or “net-issue” exercise (a
“Cashless Exercise”) by delivering to the Company (A) the Notice of Exercise and (B) the original Warrant, pursuant
to which the Holder shall surrender the right to receive upon exercise of this Warrant, a number of Warrant Shares having a value (as
determined below) equal to the Aggregate Exercise Price, in which case, the number of Warrant Shares to be issued to the Holder upon such
exercise shall be calculated using the following formula:

X = Y * (A - B)

A

 

	 	with:	X =	the number of Warrant Shares to be issued to the Holder

 

		Y =	the number of Warrant Shares with respect to which the Warrant is being exercised

 

		A =	the fair value per share of Common Stock on the date of exercise of this Warrant

 

		B =	the then-current Exercise Price of the Warrant

 

Solely for the purposes of this paragraph, “fair
value” per share of Common Stock shall mean the average Closing Price (as defined below) per share of Common Stock for the
twenty (20) Trading Days immediately preceding the date on which the Notice of Exercise is deemed to have been sent to the Company. “Closing
Price” means, for any date, the price determined by the first of the following clauses that applies:  (a) if the
Common Stock is then listed or quoted on the NASDAQ Capital Market or any other national securities exchange, the closing price per share
of the Common Stock for such date (or the nearest preceding date) on the primary eligible market or exchange on which the Common Stock
is then listed or quoted; (b) if prices for the Common Stock are then quoted on the OTC Bulletin Board or any tier of the OTC Markets,
the closing bid price per share of the Common Stock for such date (or the nearest preceding date) so quoted; or (c) if prices for the
Common Stock are then reported in the “Pink Sheets” published by the National Quotation Bureau Incorporated (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent closing bid price per share of the Common Stock
so reported. If the Common Stock is not publicly traded as set forth above, the “fair value” per share of Common Stock shall
be reasonably and in good faith determined by the Board of Directors of the Company as of the date which the Notice of Exercise is deemed
to have been sent to the Company. “Trading Day” means a day on which the Common Stock is traded on an applicable
national securities exchange, on the OTC Bulletin Board or otherwise.

 

For purposes of Rule 144 promulgated under the Securities Act, it is
intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have been acquired
by the Holder, and the holding period for such shares shall be deemed to have commenced, on the date of issuance of this Warrant.

 

(b) Partial Exercise. If this Warrant is
exercised in part only, the Company shall, upon surrender of this Warrant, execute and deliver, within 10 days of the date of exercise,
a new Warrant evidencing the rights of the Holder, or such other person as shall be designated in the Notice of Exercise, to purchase
the balance of the Warrant Shares purchasable hereunder. If the Holder exercises this Warrant or attempts to exercise this Warrant before
the Company shall have delivered to the Holder a new Warrant as contemplated above, then the Holder shall be deemed to have validly exercised
this Warrant pursuant to this Section 2 without having complied with the requirements of Section 2(a)(ii). In
no event shall this Warrant be exercised for a fractional Warrant Share, and the Company shall not distribute a Warrant exercisable for
a fractional Warrant Share. Fractional Warrant Shares shall be treated as provided in Section 7 hereof.

 

(c) Effect of Exercise. Upon the exercise
of the rights represented by this Warrant, shares of Common Stock shall be issued for the Warrant Shares so purchased, and shall be registered
in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, on or before the second (2nd) business
day after the rights represented by this Warrant shall have been so exercised and shall be issued in certificate or book-entry form and
delivered to the Holder, if so requested. The person in whose name any Warrant Shares are to be issued upon exercise of this Warrant shall
be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise
Price was made, irrespective of the date of issuance of the shares of Common Stock, except that, if the date of such surrender and payment
is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares
at the close of business on the next succeeding date on which the stock transfer books are open.

 

    2

     

    

 

		3.	COVENANTS OF THE COMPANY.

 

(a) Covenants as to Warrant Shares. If
at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the
Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares
of Common Stock (or other securities as provided herein) to such number of shares as shall be sufficient for such purposes.

 

(b) No Impairment. Except and to the extent
as waived or consented to by the Holder or otherwise in accordance with Section 2 hereof, the Company will not, by amendment
of its Certificate of Incorporation (as such may be amended from time to time), or through any means, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in
the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order
to protect the exercise rights of the Holder against impairment.

 

(c) Notices of Record Date. In the event
of any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof
who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or
other distribution, the Company shall mail to the Holder, at least ten (10) days prior to the record date, a notice specifying the
date on which any such record is to be taken for the purpose of such dividend or distribution.

 

		4.	REPRESENTATIONS OF HOLDER.

 

(a) Acquisition of Warrant for Personal Account.
The Holder represents and warrants that it is acquiring the Warrant and the Warrant Shares solely for its account for investment and not
with a present view toward the public distribution of said Warrant or Warrant Shares or any part thereof and has no intention of selling
or distributing said Warrant or Warrant Shares or any arrangement or understanding with any other persons regarding the sale or distribution
of said Warrant or Warrant Shares, except as would not result in a violation of the Securities Act. The Holder will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of)
the Warrant except in accordance with the Securities Act and will not, directly or indirectly, offer, sell, pledge, transfer or otherwise
dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the Warrant Shares except in accordance with
the provisions of the Securities Act.

 

(b) Securities Are Not Registered.

 

The Holder understands that the offer and sale
of the Warrant or the Warrant Shares have not been registered under the Securities Act on the basis that no distribution or public offering
of such securities of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding
its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future,
selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The
Holder has no such present intention.

 

The Holder recognizes that the Warrant and the
Warrant Shares may have to be held indefinitely unless the resale thereof is subsequently registered under the Securities Act or an exemption
from such registration is available. Except as provided in a separate registration rights agreement between the Holder and the Company,
the Holder recognizes that the Company has no obligation to register the Warrant or the Warrant Shares, or to comply with any exemption
from such registration.

 

The Holder is aware that neither the Warrant nor
the Warrant Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met, including, among
other things, the availability of certain current public information about the Company and the required holding period under Rule 144
being satisfied. Holder is aware that any such sale made in reliance on Rule 144, if Rule 144 is available, may be made only in accordance
with the terms of Rule 144.

 

(c) Disposition of Warrant and Warrant Shares.
The Holder understands and agrees that all certificates evidencing the Warrant Shares to be issued to the Holder may bear a legend in
substantially the following form:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF
A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE RESALE OF THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A
OF SUCH ACT.

 

    3

     

    

 

		5.	CHANGES IN OUTSTANDING SHARES.

 

In the event of changes in the outstanding Common
Stock by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations,
reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Exercise
Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total
number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder
continued to hold such shares until after the event requiring adjustment. The form of this Warrant need not be changed because of any
adjustment in the number, class, and kind of shares subject to this Warrant. The Company shall promptly provide a certificate from an
authorized officer notifying the Holder in writing of any adjustment in the Exercise Price and/or the total number, class, and kind of
shares issuable upon exercise of this Warrant, which certificate shall specify the Exercise Price and number, class and kind of shares
under this Warrant after giving effect to such adjustment.

 

		6.	SALE OF THE COMPANY.

 

In the event of a Sale of the Company, then the Company shall ensure
that lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis
and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of
this Warrant only as provided for in Section 2(a)(iii)(1), such shares of stock, securities or assets (including cash) as would have been
issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore
issuable upon exercise of this Warrant, had such Sale of the Company not taken place, and in any such case appropriate provision shall
be made with respect to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provision
for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any share
of stock, securities or assets (including cash) thereafter deliverable upon the exercise thereof. The Company shall not effect any Sale
of the Company unless prior to or simultaneously with the consummation thereof the successor entity (if other than the Company) resulting
from such Sale of the Company, or the entity purchasing or otherwise acquiring such assets or other appropriate corporation or entity
shall assume the obligation to deliver to the Holder, at the last address of the Holder appearing on the books of the Company, such shares
of stock, securities or assets (including cash) as, in accordance with the foregoing provisions, the Holder may be entitled to purchase,
and the other obligations under this Warrant. The provisions of this Section 6 shall similarly apply to successive Sales of
the Company.

 

		7.	FRACTIONAL SHARES, ADJUSTMENT OF EXERCISE PRICE.

 

No fractional shares shall be issued upon the exercise of this Warrant
as a consequence of any adjustment pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may
be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the
Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market
value of a Warrant Share by such fraction. No adjustment in the Exercise Price shall be required unless such adjustment would require
an increase or decrease of at least $0.0001; provided, however, that any adjustments which by reason of this Section 7 are not
required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this Section
7 shall be made to the $0.0001 or to the nearest 1/100th of a share, as the case may be.

 

		8.	NO STOCKHOLDER RIGHTS.

 

This Warrant in and of itself shall not entitle the Holder to any voting
rights or, except as otherwise set forth herein, other rights as a stockholder of the Company.

 

		9.	RESERVATION OF SHARES.

 

The Company shall at all times reserve and keep available out of its
authorized but unissued shares Common Stock no less than 100% of the maximum number of shares of Common Stock issuable upon full exercise
of the Warrant.

 

		10.	TRANSFER OF WARRANT.

 

Subject to applicable laws and compliance with Section 4(c)
hereof, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery
of this Warrant and the form of assignment attached hereto to any transferee designated by Holder.

 

    4

     

    

 

		11.	LOST, STOLEN, MUTILATED OR DESTROYED WARRANT.

 

If this Warrant is lost, stolen, mutilated or destroyed, the Company
may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include
the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any
such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated
or destroyed Warrant shall be at any time enforceable by anyone.

 

		12.	MODIFICATIONS AND WAIVER.

 

Provisions of this Warrant may be amended or modified, or a provision
or requirement hereof waived, only with the written consent of the Company and the Holder.

 

		13.	NOTICES, ETC.

 

All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given as specified in the Placement Agent Agreement.

 

		14.	ACCEPTANCE.

 

Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.

 

		15.	GOVERNING LAW.

 

This Warrant shall be construed and enforced in accordance with, and
all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.
The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or
that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing
suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Holder,
to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the
Holder. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL
FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

		16.	DESCRIPTIVE HEADINGS.

 

The descriptive headings of the several paragraphs of this Warrant
are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to
its fair meaning without regard to which party drafted this Warrant.

 

		17.	SEVERABILITY.

 

The invalidity or unenforceability of any provision of this Warrant
in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision
of this Warrant, which shall remain in full force and effect.

 

		18.	ENTIRE AGREEMENT.

 

This Warrant and the Placement Agent Agreement between the Holder and
the Company dated January 27, 2021, constitute the entire agreement between the parties pertaining to the subject matter contained in
it and supersede all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written,
with respect to such subject matter.

 

[Signature Page Follows]

 

    5

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its duly authorized officer as of January 31, 2021.

 

	 	rEVELATION BIOSCIENCES, INC.
	 	 
	 	By:	 
	 	Name:	 Chester S. Zygmont, III
	 	Title: 	Chief Financial Officer
	 	 
	 	Address for Notice:
	 	 
	 	Revelation Biosciences
	 	350 Sharon Park Drive, R4
	 	Menlo Park, CA 94025
	 	Attention: James Rolke, Chief Executive Officer

 

	National Securities corporation	 
	 	 
	By:	 	 
	Name: 	Jeff Sacher 	 
	Title: 	Senior Managing Director	 
	 	 
	Address for Notice:	 
	 	 
	National Securities Corporation 	 
	200 Vesey Street, 25th Floor	 
	New York, NY 10281	 
	Jeff Sacher, Senior Managing Director	 

 

[Signature Page to Warrant]

 

     

     

    

 

NOTICE OF EXERCISE

 

TO: revelation BIOSCIENCES,
INC.

 

(1) The undersigned hereby irrevocably elects to exercise this
Warrant and to purchase thereunder, ___________________ full shares of Revelation Biosciences, Inc. Common Stock issuable upon exercise
of the Warrant and delivery of:

 

		●	$_________ (in cash as provided for in the foregoing Warrant) and any applicable taxes payable by the
undersigned pursuant to such Warrant; and

 

		●	__________ shares of Common Stock (pursuant to a Cashless Exercise in accordance with Section 2(a)(iii)(2)
of the Warrant) (check here if the undersigned desires to deliver an unspecified number of shares equal the number sufficient to effect
a Cashless Exercise [___]).

 

(2) Please issue a certificate or certificates representing
said shares of Common Stock in the name of the undersigned or in such other name as is specified below:

 

 

(Name)

 

 

(Address)

 

(3) If the shares issuable upon this exercise
of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire upon the exercise of the Warrant, the undersigned
requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered to:

 

 

(Name)

 

 

(Address and social security or federal employer identification number
(if applicable))

 

(4) The undersigned represents that (i) the aforesaid shares
of Common Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection
with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares in violation
of the Securities Act of 1933, as amended (the “Securities Act”); (ii) the undersigned is aware of the
Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed
and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of
this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits
and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that the issuance
of the shares of Common Stock upon exercise of this Warrant has not been registered under the Securities Act by reason of a specific exemption
from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the
investment intent as expressed herein, and, because the issuance of such securities has not been registered under the Securities Act,
such securities must be held indefinitely unless the resale thereof is subsequently registered under the Securities Act or an exemption
from such registration is available; (v) the undersigned is aware that the aforesaid shares of Common Stock may not be sold pursuant
to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the time
period prescribed by Rule 144, that among the conditions for use of Rule 144 is the availability of current information to the public
about the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of Common
Stock unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and
such disposition is made in accordance with said registration statement, or the undersigned has furnished the Company with an opinion
of counsel, reasonably satisfactory to the Company, to the effect that such disposition is not required to be registered pursuant to the
Securities Act or any applicable state securities laws; provided, that no opinion shall be required for any disposition made or
to be made in accordance with the provisions of Rule 144.

 

	Date:	 		Signature:	 
	 	 	 
		 	Print Name: 	 

 

     

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, subject to compliance with Section
4(c) hereof, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to:

 

 

(Name)

 

 

(Address)

 

Dated: ________________, 20___

 

	 	Holder’s Name:	 
		Holder’s Signature: 	 
	 	Holder’s Address:	 
	 	 	 
	 	 	 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit 10.14

 

EXECUTION VERSION

 

December 31, 2020

 

Revelation Biosciences, Inc.

 

Re: Global Health Agreement

 

Ladies and Gentlemen:

 

This global health letter
agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the
“Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”)
in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”)
in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase
Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).

 

The Investor is making the
Investment pursuant to the terms of this Global Health Agreement, the Purchase Agreement, the Investors’ Rights Agreement, the Voting
Agreement and the Right of First Refusal and Co-Sale Agreement, each of which are dated as of even date herewith (collectively, the “Investment
Documents”).

 

1. Background.

 

(a) The
Company is a California-based company that is developing medical diagnostics and therapeutics addressing viral infections.

 

(b) One
of the Investor’s objectives is to improve global health through the provision of funding to address certain global health challenges
by supporting the development, production and commercialization of drugs, vaccines, medical devices, preventatives, diagnostics and other
related technology targeting global health conditions, including in low- and lower-middle income countries. The Investor has determined
that the Investment has offered, or will offer, significant potential to improve global health in such countries.

 

2. Term

 

The term of this Global Health
Agreement shall end on the six (6) year anniversary of the Initial Closing under the Purchase Agreement (“Term”).

 

3. Program
Product

 

The Global Health Agreement
relates to the following programs of the Company: REVTx-99 (“Program Therapeutic”) and REVDx-501(“Program Diagnostic”)
(together “Program Products”).

 

4. Program-Related
Investment Requirements

 

In consideration of the Investor
making, or having made, the Investment on the terms and conditions stated herein and in the Investment Documents, and for other good and
valuable consideration, the undersigned hereby agree as follows:

 

(a) Purposes
and Use of Funds

 

(i) Certain
key purposes of the Investment are to provide relief to the poor and distressed, improve the health of those living in Low and Lower-Middle
Income Countries (as defined by the World Bank and if approved by the Global Access Committee) (“Target Countries”), and educate
health practitioners and public health officials on cost-effective technologies that will improve the health and safety of poor and low-income
individuals globally (the “Global Health Objectives”). A portion of proceeds of the Investment will be used by the Company
to conduct clinical studies and achieve regulatory approvals for the Program Products, and to otherwise carry out the Global Access Commitments
set forth below (collectively, the “Use of Proceeds”).

     

     

    

 

(ii) The
Company acknowledges and understands that a key purpose of the Investor making the Investment is to advance the Global Heath Objectives
while seeking a financial return consistent with the Investor’s objectives. The Company confirms it has available personnel to provide
available documents to assist in Target Countries, as approved by the Global Access Committee.

 

(b) Global
Access Commitments

 

(i) Beginning
on the date of this Global Health Agreement, the Company shall conduct the following activities to advance the Global Health Objectives
during the Term:

 

(1) The
Company shall use commercially reasonable efforts to obtain FDA approvals and clearances, as appropriate for the Program Products.

 

(2) The
Company shall make Program Products available to non-profit organizations and public-sector purchasers in Target Countries (“Global
Health Purchasers”) at a price of no more than 30% above the Company’s COGS, in Low-Income Countries and in Low-Middle-Income
Countries, if approved by the Global Access Committee (as defined below); provided, however, that any non-profit organization and public-sector
purchaser located in Brazil, India, South Africa and Mexico shall need to be approved by the Global Access Committee before qualifying
as a “Global Health Purchaser” within the terms of this Global Health Agreement.

 

(3) The
volume of Program Products made available for the Global Health Purchasers under Section 4(b)(i)(2) above shall meet the demands of the
Global Health Purchasers, as confirmed by the Global Access Committee, up to 20% of the Company’s annual unit sales volume (unless
adjusted jointly by a majority of the Board of Directors and Global Access Committee); it being understood, however, that the Company
shall have the right to supply more at its sole discretion.

 

(4) Beginning
in the year immediately following year in which any Program Product receives European or FDA approval/clearance, the Company shall allocate
$50,000 per year to the Global Access Committee to work on training programs to be conducted by the Company or by partners approved by
the Global Access Committee, such as the WHO, Gates Foundation and others, in Target Countries on the use of the Program Products with
a target of training leading practitioners each year in the Target Countries, as defined by the Global Access Committee, as well as to
work on access and promoting demand in the Target Countries.

 

(5) The
Company shall work with global health authorities and partner organizations, including but not limited to the World Health Organization,
the Clinton Health Access Initiative (CHAI), and the Bill & Melinda Gates Foundation (BMGF) and use commercially reasonable efforts
to have the Program Products added to protocols and treatment guidelines.

 

(ii) The
Global Access Commitments set forth in this Section 4 shall continue for the Term and shall be fully enforceable by the Investor, notwithstanding
any other provision of the Investment Documents.

 

(iii) In
the event that the Program Products are acquired directly or through an acquisition of the Company by a third party, the Global Access
Commitments contained in this Global Health Agreement shall continue to survive for the Term and shall be assumed by the acquirer.

 

(c) Global
Health License

 

(i) The
Company hereby grants the Investor a nonexclusive, perpetual, irrevocable, non-terminable, fully-paid up, royalty free license in Target
Countries for Global Health Purchasers and for the sole purpose of achieving the Global Access Commitments (with the right to sublicense
to third parties reasonably acceptable to the Company) to the Program Products to use, reproduce, modify, make, have made, distribute,
sell and otherwise dispose of such Products in the Target Countries (“Global Health License”). The Global Health License is
a present license but the Investor will not exercise their rights under such license except in the event of a License Trigger Event as
defined below.

 

    2

     

    

 

(ii) A
License Trigger Event means:

 

(1) the
Company fails to use commercially reasonable efforts to obtain regulatory approvals, as agreed by the Global Access Committee;

 

(2) the
Company fails to cure an Event of Non-Compliance, including a failure to perform the Global Access Commitments, within the applicable
time period (it being understood that the exercise of the Investor’s rights under the Global Health License, and the Investor’s
rights to transfer its Shares under the terms of the side letter between the Company, the Investor and certain other individuals named
therein, dated as of even date herewith, shall be its sole and exclusive remedies following the Company’s failure to cure an Event
of Non-Compliance);

 

(3) the
Company or any transferee assigns or transfers (including by exclusive license) any material intellectual property to the Products or
other intellectual property subject to the Global Access Commitments and the successor fails to assume or perform the relevant Global
Access Commitments; or

 

(4) the
Company or any transferee (1) institutes any bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, dissolution, liquidation,
assignment for the benefit of creditors, or similar proceeding relating to it under the laws of any jurisdiction or any such proceeding
is instituted against the Company or any transferee that remains undismissed or unstayed for a period of 90 days, or (2) ceases to conduct
business in the ordinary course or is determined to no longer be a going concern. Notwithstanding the foregoing, a License Trigger Event
will not be deemed to have occurred if the Company or its transferee voluntarily or involuntarily files a Chapter 7 liquidation proceeding
that is converted to a reorganization proceeding within 60 days after filing; provided, that the Company or its transferee continues to
perform its Global Access Commitments.

 

(iii) In
the event that the Investor exercises its rights to the Global Health License under this Section 4(c) pursuant to a License Trigger Event,
and the Program Products distributed under such Global Health License in the Target Countries subsequently appear for sale or distribution
in commercial marketplaces of the Target Countries or non-Target Countries (“Grey Market Sales”), then the Company or any
transferee may give notice to the Investor. Following receipt of such notice by the Investor, the Company or any transferee and the Investor
will work together to identify how the Program Products intended for Global Health Purchasers arrived in the commercial marketplace. During
such investigation, the Company or any transferee may request that the Investor suspend distribution and/or sales to certain organizations
if those organizations are identified as being involved in Grey Market Sales, and the Investor will respond in a timely manner to any
such request. Following such investigation, the Company or any transferee and the Investor agree to take any such corrective measures
to prevent additional Grey Market Sales, including ceasing sales to the identified parties on a permanent basis.

 

(d) Global
Access Committee and Global Access Coordinator

 

Promptly following the execution
of this Global Health Agreement or at an alternate time approved by the Company Board of Directors and the AXA board representative, the
Company will form a joint steering committee (the “Global Access Committee”) to oversee the Company’s efforts in Target
Countries. The Global Access Committee shall be comprised of up to four (4) members: (i) one individual appointed by the Company; (ii)
one individual appointed by the Investor (the “AXA IM Prime Impact Fund Appointee”); and (iii) up to two additional individuals
unaffiliated with the Company or the Investor, and appointed upon mutual agreement of the Company and the Investor. Decisions on the Global
Access Committee shall be made by majority vote, including the affirmative vote of the AXA IM Impact Fund Appointee.

 

The Global Access Coordinator,
who shall initially be David Shoultz (or another person mutually agreeable to the Company and AXA IM Impact Fund), will lead the Company’s
efforts to market the Products to Global Health Purchasers in Target Countries and to ensure overall customer success in Target Countries,
in accordance with a plan to be prepared by the Global Access Committee on or prior to March 31, 2021 (the “Global Access Plan”).
The activities of the Global Access Coordinator, which activities shall be consistent with the Global Access Plan, shall be overseen jointly
by the Company’s senior management and the Global Access Committee.

 

    3

     

    

 

(e) Required
Reporting

 

(i) In
addition to any and all reports required to be delivered to the Investor under the Investment Documents, the Company shall furnish, or
cause to be furnished, to the Investor (by way of its investment advisor, Global Health Investment Advisors, LLC (“GHIA”)),
the following reports and certifications (the “PRI Reports”):

 

(1) within
90 days after the end of each fiscal year of the Company during the term of the Investment, a certificate, signed by an officer of the
Company, (a) certifying that the requirements of the Investment, as set forth in this Global Health Agreement and the Investment Documents,
were met during the immediately preceding year, and (b) describing the use of the proceeds of the Investment and evaluating the Company’s
progress toward achieving the key purposes of the Investment, including specifically the covenants regarding the Global Access Commitments
described in Section 4 of this Global Health Agreement, and the activities and the use of the funds towards such purposes;

 

(2) within
90 days after the end of the fiscal year of the Company during which this Agreement terminates, a certificate, signed by an officer of
the Company, (a) certifying that the requirements of the Investment, as set forth in this Global Health Agreement and the Investment Documents,
were met during the term of the Investment, (b) describing the material activities of the Company with respect to the Investment and generally
the Use of Proceeds made during the entire period in which the Investment was outstanding, and (c) evaluating the progress toward achieving
the key purposes of the Investment;

 

(3) within
90 days after the end of each fiscal year of the Company during the Term, the Company shall furnish, or cause to be furnished, full and
complete financial reports related to the Investment of the type ordinarily required by the Company’s commercial and public investors
under similar circumstances, including but not limited to the use of the Investor’s funds; and

 

(4) within
75 days after the end of each fiscal quarter of the Company, a quarterly written report (which report may be informal to the extent it
contains the information requested in this Section 4(e)(4)) on the impact performance relative to the Program Products, together with
information on the impact key performance indicators (“Impact KPIs”) achieved that are aligned with the Investor’s objectives
to improve global health. For the purposes of the foregoing, the priority Impact KPIs are:

 

	
     

    IPI No
	 	Target Outcome	 	Performance Indicators
	IPI -1	 	Program Product	 	Regulatory approvals in target countries
	IPI - 2	 	Program Products	 	Number of Company Products catalyzed/distributed 
	IPI -3	 	Lives Improved	 	Number of Lives improved by the provision of the Program Products in LMICs
	IPI -4	 	Reach	 	Number of Low – Middle Income Countries benefitting from the Program Products

 

(f) Maintenance
of Objectives; Events of Non-Compliance

 

The Company shall utilize
the proceeds of the Investment solely for the purposes set forth in the Investment Documents and, in particular, to advance the objectives
described in Section 4 of this Global Health Agreement and in a manner consistent with the terms and provisions of this Global Health
Agreement. If the Company fails to operate in accordance with such purposes or has failed to comply with the provisions of this Global
Health Agreement (an “Event of Non-Compliance”), it shall notify the Investor in writing within 60 days of such Event of Non-Compliance
and shall describe the steps the Company shall take to rectify the situation within 60 days of the notification. Notwithstanding the foregoing
sentence, if the Investor believes an Event of Non-Compliance has occurred, it shall notify the Company in writing of such Event of Non-Compliance.
Such notification shall clearly specify the basis for the Investor’s determination and request that the Company rectify the specified
Event of Non-Compliance within 60 days following the date of the notification.

 

    4

     

    

 

(g) Transfer

 

The Company shall have the
right to transfer or assign its obligations under this Global Health Agreement without the prior written consent of the Investor, subject
to the following conditions being met: (a) at least five (5) business days prior to closing of the transaction, the Company provides the
Investor with written notice of the proposed transfer, and the Investor does not object to such assignment or transfer within five (5)
days of receipt of such notice; (b) the transferee agrees in writing to be legally bound to the relevant Global Access Commitments as
set forth herein, and (c) the Company provides a copy of such written commitment by the transferee within five (5) business days of closing
of the transaction. Any attempted assignment in violation of this provision shall be null and void ab initio. If third party requires
a separate license agreement with the Investor, the Investor shall use commercially reasonable efforts to put such agreement in place
in a timely manner, subject to such third party agreeing to reimburse the Investor for legal fees not to exceed $10,000.

 

(h) Access
to Records

 

The Company shall maintain
books and records adequate to support the information in the PRI Reports and to provide the information ordinarily required by commercial
investors under similar circumstances, and the Company shall make such books and records available to the Investor, GHIA, and a designee
of the Investor at reasonable times and under reasonable circumstances for inspection by the Investor or GHIA. Such books and records
shall be maintained and made available to the Investor for at least six (6) years after the termination of its Investment.

 

(i) Promotion
of Terrorist Activities

 

In compliance with the provisions
of the USA Patriot Act of 2001, Pub. L. No. 107-56, 115 Stat. 272, as amended, and U.S. Executive Order 13224, the Company represents
that it will not promote or support terrorist activities and that it will not provide any proceeds of the Investment to any entity or
individual that promotes or engages in such activities.

 

(j) Environmental,
Social and Governance Requirements

 

The Company shall comply with
the environmental, social and governance (“ESG”) requirements set forth on Exhibit 1 and observe the referenced International
Finance Corporation (“IFC”) performance standards.

 

(k) Anti-Corruption
Requirements

 

The Company shall comply with
the anti-corruption requirements set forth on Exhibit 2.

 

5. Miscellaneous

 

(a) Entire
Agreement; Modification

 

The terms and conditions set
forth in this Global Health Agreement are in addition to the provisions stated in any other documents executed between the Investor and
the Company, and the terms and conditions of this Global Health Agreement shall prevail over any inconsistent provision in any such other
document, including without limitation the Investment Documents. All references to Sections shall be deemed to refer to sections of this
Global Health Agreement unless otherwise specifically stated herein. No change, modification or waiver of any term or condition of this
Global Health Agreement shall be valid unless it is in writing, it is signed by the Company and the Investor, and it expressly refers
to this Global Health Agreement.

 

(b) Authority;
Governing Law

 

Each of the signatories below
covenants, represents and warrants that it has all power and authority necessary to enter into this Global Health Agreement, that its
execution of this Global Health Agreement has been duly authorized by all necessary action and that, on execution, it will be fully binding
and enforceable in accordance with its terms, and that no other consents or approvals of any other person or third parties are required
or necessary for this Global Health Agreement to be so binding. This Global Health Agreement shall be governed by the laws of the State
of Delaware without regard to its conflict of law provisions.

 

(c) Counterparts

 

This Global Health Agreement
may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall be deemed to be and constitute
one and the same instrument.

 

[Remainder of page intentionally left blank.]

 

    5

     

    

 

IN WITNESS WHEREOF,
the parties have caused to be executed this Global Health Agreement effective as of December __, 2020.

 

	 	Revelation Biosciences, Inc.
	 	 
	 	By: 	                          
	 	Name:	 
	 	Title:	 

 

    6

     

    

 

IN WITNESS WHEREOF,
the parties have caused to be executed this Global Health Agreement effective as of December __, 2020.

  

	 	Agreed on behalf of AXA Investment
Managers UK Limited, in its capacity as Investment Manager to:
	 	 
	 	AXA IM PRIME IMPACT MASTER FUND I SCA SICAV-RAIF  
	 	 
	 	By:	 
	 	Name: 	Josephine Tubbs
	 	Title:	Authorised Signatory

 

    7

     

    

 

Exhibit 1

 

Investee ESG Requirements

 

1. In connection with any proposed investment:

 

		i.	Before any investment, AXA IM Impact Fund will review and investigate information available in the public
domain regarding any adverse impact on local communities or the environment or adverse environmental or social performance associated
with the project and use that information provisionally to designate the proposed investment a Category A, Category B or a Category C
Client/Activity (as defined below). In addition, AXA IM Impact Fund will perform an ES&G due diligence including a review of regulatory
and applicable legal environmental and governance compliance and compliance with the IFC Performance Standards on Environmental and Social
Sustainability - Effective January 1, 2012 of the proposed investee. Due diligence findings will be documented in an Environmental Social
and Governance due diligence report (“ES&G Due Diligence Report”). In the event that there are any items that require
corrective action, a corrective action plan will be provided to the Company. Based on this due diligence, the initial categorization shall
be either confirmed or revised to reflect the nature of the proposed investment.

 

		ii.	In connection with any capital call (or other application of AXA IM Impact Fund capital) for the proposed
investment, AXA IM Impact Fund will confirm (a) the categorization of the operations of the related Industry Partner (whether proposed
or existing), (b) the rationale for such categorization, and (c) that AXA IM Impact Fund has applied the ES&G Management System in
accordance with the ES&G Requirements with respect to the proposed investment.

 

		iii.	AXA IM Impact Fund will only make an investment in a company (including a new or follow-on investment
in an existing portfolio company) if: (i) any identified adverse impact or performance has been resolved in accordance with the ES&G
Requirements and these ES&G provisions; or (ii) the company has agreed a corrective action plan to so resolve the identified adverse
impacts or performance within a reasonable timeline (including appropriate conditions precedent for the proposed investment), and the
investment documentation includes appropriate remedies if the proposed Industry Partner fails to implement that plan.

 

2. Definitions.

 

		“Applicable ES&G Law”	 All applicable statutes, laws,
ordinances, rules and regulations, including, but not limited to, any license, permit or other governmental Authority imposing liability
or setting standards of conduct concerning any environmental, social, labor, health and safety or security risks of the type contemplated
by the Performance Standards.

 

		“Authority” Any	national, supranational, regional or local government or governmental, administrative,
fiscal, judicial, or government-owned body, department, commission, authority, tribunal, agency or entity.
	 	 	 
	 	“Category A Activity”	Any activity of an Industry Partner which is likely to have
significant adverse environmental or social risks and/or impacts that are diverse, irreversible or unprecedented.
	 	 	 
	 	“Category
A Client” 	An Industry Partner that carries or intends to carry out a Category A Activity.
	 	 	 
	 	“Category
B Activity” 	Any activity of an Industry Partner which is likely to have limited adverse environmental or social risks and/or
impacts that are few in number, generally site-specific, largely reversible and readily addressed through mitigation measures.

	 	 	 
	 	“Category
B Client” 	An Industry Partner that carries or intends to carry out a Category B Activity.
	 	 	 
	 	“Category
C Activity” 	Any activity of an Industry Partner which is likely to have minimal or no adverse environmental or social risks and/or
impacts.

	 	 	 
	 	“Category
C Client”	An Industry Partner that carries or intends to carry out a Category C Activity.
	 	 	 
	 	“ES&G
Due Diligence Report”	The environmental social and governance due diligence report prepared by Global Health Investment Advisors,
LLC (the “Investment Manager”) in connection with a proposed Investment by AXA IM Impact Fund.

 

    8

     

    

 

	 	“ES&G
Performance Report”	A written report prepared by the Investment Manager, evaluating the social and environmental performance
of the Company and the portfolio companies for the previous fiscal year, describing in reasonable detail (i) implementation and operation
of the ES&G Management System, (ii) the environmental and social performance of the portfolio companies, and (iii) as applicable,
compliance by portfolio companies with any applicable portfolio company action plans.

	 	 	 
	 	“ES&G
Requirements”	The social and environmental obligations to be undertaken by the portfolio companies to ensure compliance with:
(i) the Exclusion List; (ii) Applicable ES&G Laws; (iii) the Performance Standards, and (iv) any other requirements established by
the ES&G Management System.

	 	 	 
	 	“Exclusion List” 	The
list of prohibited activities set forth below.
	 	 	 
	 	“Performance
Standards”	IFC’s Performance Standards on Social & Environmental Sustainability, dated January 1, 2012.

 

3. AXA IM IMPACT FUND Exclusion List

 

AXA IM Impact Fund will apply the following
exclusions:

 

		−	Production or trade in any product or activity deemed illegal under host country laws or regulations or
international conventions and agreements, or subject to international bans, such as pharmaceuticals, pesticides/herbicides, ozone depleting
substances, PCB’s, wildlife or products regulated under CITES.
	 	 	 
	 	−	Production or trade in weapons
and munitions.
	 	 	 
	 	−	Production or trade in alcoholic
beverages (excluding beer and wine).
	 	 	 
	 	−	Production or trade in tobacco.
	 	 	 
	 	−	Gambling, casinos and equivalent
enterprises.

 

		−	Production or trade in radioactive materials. This does not apply to the purchase
of medical equipment, quality control (measurement) equipment and any equipment where IFC considers the radioactive source to be trivial
and/or adequately shielded.

 

		−	Production or trade in unbonded asbestos fibers. This does not apply to purchase
and use of bonded asbestos cement sheeting where the asbestos content is less than 20%.
	 	 	 
	 	−	Drift net fishing in the
marine environment using nets in excess of 2.5 km. in length.

 

		−	Production or activities involving harmful or exploitative forms of forced
                                                                    labor1 /harmful child labor2.
	 	 	 
	 	−	Commercial logging operations
for use in primary tropical moist forest.

 

		−	Production or trade in wood or other forestry products other than from sustainably
managed forests.

 

 

1
Forced labor means all work or service, not voluntarily performed, that is extracted from an individual under threat of force or penalty.

2
Harmful child labor means the employment of children that is economically exploitive, or is likely to be hazardous to, or
to interfere with, the child’s education, or to be harmful to the child’s health, or physical, mental, spiritual, moral,
or social development.

 

    9

     

    

 

Exhibit 2

 

IFC ANTI-CORRUPTION GUIDELINES

 

Compliance with United Nations
Security Council Resolutions. AXA IM Impact Fund shall ensure that the Company, consistent with the business and investment profile of
AXA IM Impact Fund, institutes, maintains and complies with internal policies and controls for the purpose of ensuring that the Company
will not enter into any transaction (i) with, or for the benefit of, any of the persons or entities named on lists from time to time promulgated
by or (ii) related to any activity from time to time prohibited by the United Nations Security Council or its committees pursuant to any
resolution issued under Chapter VII of the United Nations Charter.

 

Sanctionable Practices. The Company shall
not engage in (nor authorize or permit any of their Affiliates or any other Person acting on their behalf to engage in), any Sanctionable
Practice defined as any Corrupt Practice, Fraudulent Practice, Coercive Practice, Collusive Practice, or Obstructive Practice, as those
terms are defined in and interpreted in accordance with the Anti-Corruption Guidelines attached hereto as Exhibit A.

 

Policy Reporting Requirements. The Company
commits that, should it become aware of any violation of the Policy Undertakings described in this Annex, it shall promptly notify the
Investment Advisor of AXA IM Impact Fund.

 

Furthermore, the Company agrees that should
IFC notify AXA IM Impact Fund of its concern that there has been a violation of the Policy Undertakings described in this Annex, the Company
shall cooperate in good faith with the Investment Advisor of AXA IM Impact Fund and IFC and its representatives in determining whether
such a violation has occurred, and shall respond promptly and in reasonable detail to any notice from IFC, and shall furnish documentary
support for such response upon IFC's request. Investment Guidelines on Policy Requirements. The Company shall not make or hold any investments
in any entity that (A) is sanctioned pursuant to United Nations Security Council resolutions issued under Chapter VII of the UN Charter;
or (B) is on the World Bank Listing of Ineligible Firms (see www.worldbank.org/debarr or any successor website or location). Divestment
of Investments Violating Investment Guideline on Policy Requirements. If AXA IM Impact Fund becomes aware that the Company is in breach
of the Policy Requirements defined under the investment, AXA IM Impact Fund may be required to use reasonable efforts to dispose of the
applicable Investment on commercially reasonable terms, taking into account liquidity, market constraints and fiduciary responsibilities.

 

Definitions.

 

“AML/CFT” means anti-money
laundering and combating the financing of terrorism;

 

“Policy Undertakings”
means the undertakings contained in paragraphs 37(a) (AML/CFT), 37(b) (Compliance with United Nations Security Council Resolutions), 37(c)
(Sanctionable Practices), 37(d) (Policy Reporting Requirements), Section 37(h) (Policy Restrictions on Transfers of Interest by Members)
and 37(i) (Investment Guidelines on

Policy Undertakings) hereof;

 

“World Bank Listing of Ineligible Firms”
means the list, as updated from time to time, of persons or entities ineligible to be awarded a World Bank Group-financed contract or
otherwise sanctioned by the World Bank Group Sanctions Board for the periods indicated on the list because they were found to have violated
the fraud and corruption provisions of the World Bank Group anticorruption guidelines and policies. The list may be found at http://www.worldbank.org/debarr
or any successor website.

 

    10

     

    

 

EXHIBIT A

 

IFC ANTI-CORRUPTION DEFINITIONS

 

The purpose of these Guidelines is to
clarify the meaning of the terms “Corrupt Practices”, “Fraudulent Practices”, “Coercive Practices”,
“Collusive Practices” and “Obstructive Practices” in the context of IFC operations.

 

1. Corrupt Practices

 

A “Corrupt Practice” is
the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another
party.

 

Interpretation

 

		a)	Corrupt Practices are understood as kickbacks and bribery. The conduct in question
must involve the use of improper means (such as bribery) to violate or derogate a duty owed by the recipient in order for the payor to
obtain an undue advantage or to avoid an obligation. Antitrust, securities and other violations of law that are not of this nature are
excluded from the definition of Corrupt Practices.

 

		b)	It is acknowledged that foreign investment agreements, concessions and other types
of contracts commonly require investors to make contributions for bona fide social development purposes or to provide funding for infrastructure
unrelated to the project. Similarly, investors are often required or expected to make contributions to bona fide local charities. These
practices are not viewed as Corrupt Practices for purposes of these definitions, so long as they are permitted under local law and fully
disclosed in the payor’s books and records. Similarly, an investor will not be held liable for corrupt or fraudulent practices committed
by entities that administer bona fide social development funds or charitable contributions.

 

		c)	In the context of conduct between private parties, the offering, giving, receiving
or soliciting of corporate hospitality and gifts that are customary by internationally-accepted industry standards shall not constitute
corrupt practices unless the action violates applicable law.

 

		d)	Payment by private sector persons of the reasonable travel and entertainment expenses
of public officials that are consistent with existing practice under relevant law and international conventions will not be viewed as
Corrupt Practices.

 

		e)	The World Bank Group does not condone facilitation payments. For the purposes of
implementation, the interpretation of “Corrupt Practices” relating to facilitation payments will take into account relevant
law and international conventions pertaining to corruption.

 

2. Fraudulent Practices

 

A “Fraudulent Practice” is any action
or omission, including misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial
or other benefit or to avoid an obligation.

 

Interpretation

 

a) An action,
omission, or misrepresentation will be regarded as made recklessly if it is made with reckless indifference as to whether it is true or
false. Mere inaccuracy in such information, committed through simple negligence, is not enough to constitute a “Fraudulent Practice”
for purposes of this agreement.

 

b) Fraudulent
Practices are intended to cover actions or omissions that are directed to or against a World Bank Group entity. It also covers Fraudulent
Practices directed to or against a World Bank Group member country in connection with the award or implementation of a government contract
or concession in a project financed by the World Bank Group. Frauds on other third parties are not condoned but are not specifically sanctioned
in IFC, Multilateral Insurance Guarantee Agency, or Partial Risk Guarantee operations. Similarly, other illegal behavior is not condoned,
but will not be considered as a Fraudulent Practice for purposes of this agreement.

 

3. Coercive Practices

 

A “Coercive Practice” is
impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly
the actions of a party.

 

AXA IM - INTERNAL

 

    11

     

    

 

Interpretation

 

		a)	Coercive Practices are actions undertaken for the purpose of bid rigging or in connection with public
procurement or government contracting or in furtherance of a Corrupt Practice or a Fraudulent Practice.

 

		b)	Coercive Practices are threatened or actual illegal actions such as personal injury or abduction, damage
to property, or injury to legally recognizable interests, in order to obtain an undue advantage or to avoid an obligation. It is not intended
to cover hard bargaining, the exercise of legal or contractual remedies or litigation.

 

4. Collusive Practices 

 

A “Collusive Practice”
is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of
another party.

 

Interpretation

 

Collusive Practices are actions undertaken for the purpose
of bid rigging or in connection with public procurement or government contracting or in furtherance of a Corrupt Practice or a Fraudulent
Practice.

 

5. Obstructive Practices

 

An “Obstructive Practice”
is (i) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making of false statements
to investigators, in order to materially impede a World Bank Group investigation into allegations of a corrupt, fraudulent, coercive or
collusive practice, and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant
to the investigation or from pursuing the investigation, or (ii) acts intended to materially impede the exercise of IFC’s access
to contractually required information in connection with a World Bank Group investigation into allegations of a corrupt, fraudulent, coercive
or collusive practice.

 

Interpretation

 

Any action legally or otherwise properly
taken by a party to maintain or preserve its regulatory, legal or constitutional rights such as the attorney-client privilege, regardless
of whether such action had the effect of impeding an investigation, does not constitute an Obstructive Practice.

 

General Interpretation 

 

A person should not be liable for actions taken
by unrelated third parties unless the first party participated in the prohibited act in question.

 

    12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]